Krystal Biotech, Inc. Shareholders' Equity
Krystal Biotech, Inc. (KRYS) had Shareholders' Equity of $1.36 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.36B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.28B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.22B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.14B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.36B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.28B 10-Q · filed 2026-08-03 |
| 2025-12-31 | $1.22B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.14B 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.04B 10-Q · filed 2026-08-03 |
| 2025-03-31 | $984.67M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $946.38M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $885.85M 10-Q · filed 2025-11-03 |
| 2024-06-30 | $838.89M 10-Q · filed 2025-11-03 |
| 2024-03-31 | $799.24M 10-Q · filed 2025-11-03 |
| 2023-12-31 | $778.64M 10-K · filed 2026-02-17 |
| 2023-09-30 | $755.95M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $653.11M 10-Q · filed 2024-11-04 |
| 2023-03-31 | $489.57M 10-Q · filed 2024-11-04 |
| 2022-12-31 | $522.23M 10-K · filed 2026-02-17 |
| 2022-09-30 | $540.77M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $559.18M 10-Q · filed 2023-11-06 |
| 2022-03-31 | $548.55M 10-Q · filed 2023-11-06 |
| 2021-12-31 | $593.58M 10-K · filed 2025-02-19 |
| 2021-09-30 | $408.24M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $418.54M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $430.65M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $292.08M 10-K · filed 2024-02-26 |
| 2020-09-30 | $301.72M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $309.70M 10-Q · filed 2021-11-08 |
| 2020-03-31 | $198.37M 10-Q · filed 2021-11-08 |
| 2019-12-31 | $202.91M 10-K · filed 2023-02-27 |
| 2019-09-30 | $207.65M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $198.29M 10-Q · filed 2020-11-09 |
| 2019-03-31 | $109.49M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $113.23M 10-K · filed 2021-03-01 |
| 2018-09-30 | $52.29M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $45.27M 10-Q · filed 2019-11-04 |
| 2018-03-31 | $47.40M 10-Q · filed 2019-11-04 |
| 2017-12-31 | $49.47M 10-K · filed 2020-03-10 |
| 2017-09-30 | $50.20M 10-Q · filed 2017-11-13 |
| 2016-12-31 | $289.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |